Microburst Insulin Infusion (MII) is a process which promotes the normalization of carbohydrate metabolism in diabetic patients. MII affects multiple organs, especially muscle, retina, liver, kidney, and nerve endings. The process involves the administration of insulin bursts similar to those found in the portal circulation of normal humans using the Bionica Microdose Infusion Device which is FDA labeled for this treatment. The process is monitored by frequent glucose level measurements. MII is done over 1-hour periods with a rest period between each session for three courses each day of treatment. Typically, MII is performed on a weekly or bi-weekly basis following the first week of two back-to-back daily sessions.
Initial Clinical Assessment
Patients report to the clinic between 7:00 am and 8:30 am for the initial clinical assessment to perform the following:
- Capture vital signs.
- Determine initial glucose level.
- Review medications.
- Assess patient’s overall condition.
- Establish an intravenous (IV) line.
MII Treatment Session
- mU / kg of Insulin, pulsed at 10 pulses/hour over 1 hour is administered by the Bionica Microdose Infusion Device programmed for the concentration, frequency and duration of pulses, and rest intervals.
- Glucose levels are taken every 30 minutes or more frequently as medically indicated in patients with a tendency for hypoglycemia.
- Oral carbohydrates are given to keep blood glucose in a specific range based on patients weight.
- There is a rest period of 30 minutes between treatments in order to stabilize blood glucose levels.
- This cycle is repeated twice more in a single treatment day.
- Patient is evaluated after the session and discharged when stable.